EFFECTS OF RejuvaMatrix ™ ON TELOMERES

Telomeres Clinical Trial

Official title:

THE EFFECTS OF THE RejuvaMatrix ™ ON TELOMERES

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04048044
• Other study ID #: HIH RM
• Status: Completed
• Phase: Phase 1
• Start date: January 2009
• Est. completion date: December 2014

Study information

• Verified date: May 2012
• Source: Holos Institutes of Health, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Lying for 30 to 60 minutes daily in a field of 75 decibels of electromagnetic energy at 54 to 78 GHz will allow telomeres of white blood cells to regenerate

Description:

Individuals who are post menopausal and who do not have an implanted electronic device, such as a pacemaker will have base line white blood cell telomeeres measured at Repeat Diagnostics in Vancouver. They will be supplied with a two inch foam mat in the center of which is copper screen with one pound of crushed sapphire. The mat looks like a mattreess and is placed on top of the regular mattress. Participants are provided with a Tesla coil to be attached to a copper wire coming from the copper screen. They will also be provided with a timer so that they can set the Tesla coil to be activated for a maximum of 60 minutes while they sleep.

Telomeres will be measured at the end of each year for 5 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: December 2014
• Est. primary completion date: December 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

-

Exclusion Criteria:

• Implanted electronic device

• Major, debilitating disease

• Person living with an individual who has an implanted device

• Person who is or could become pregnant

Related Conditions & MeSH terms

• Telomeres

Intervention

Device:
• Exposure to GHz electromagnetic energy (RejuvaMatrix)
75 decibels of 54 to 78 GHz daily for 60 minutes

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Holos Institutes of Health, Inc

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Length of telomeres after 5 years compared with baseline		5 years
Secondary	Total Symptom Index		5 years